[
  {
    "text": "protection and deceptive trade practices, including any state anti-kickback/fraud and abuse related laws, all as amended from time",
    "bbox": [
      111,
      141,
      1000,
      157
    ],
    "label": 5,
    "category": "Expiration Date"
  },
  {
    "text": "to time.",
    "bbox": [
      111,
      161,
      174,
      174
    ],
    "label": 5,
    "category": "Expiration Date"
  },
  {
    "text": "1.8 'Business Day' means each day of the week, excluding Saturday, Sunday or a day on which banking institutions in",
    "bbox": [
      180,
      195,
      1000,
      210
    ],
    "label": 5,
    "category": "Expiration Date"
  },
  {
    "text": "New York, New York. USA are closed..",
    "bbox": [
      111,
      216,
      455,
      229
    ],
    "label": 5,
    "category": "Expiration Date"
  },
  {
    "text": "1.9 \"Calendar Quarter\"' shall mean each successive period of three (3) calendar months commencing on January 1, April.",
    "bbox": [
      179,
      249,
      1000,
      266
    ],
    "label": 5,
    "category": "Expiration Date"
  },
  {
    "text": "1, July 1 and October 1, except that the first Calendar Quarter of the Term shall commence on the Effective Date and end on the",
    "bbox": [
      113,
      271,
      1000,
      284
    ],
    "label": 5,
    "category": "Expiration Date"
  },
  {
    "text": "day immediately prior to the first to occur of January 1, April 1, July 1 or October 1 after the Effective Date, and the last Calendar",
    "bbox": [
      112,
      290,
      1000,
      304
    ],
    "label": 5,
    "category": "Expiration Date"
  },
  {
    "text": "Quarter shall end on the last day of the Term..",
    "bbox": [
      114,
      310,
      493,
      322
    ],
    "label": 5,
    "category": "Expiration Date"
  },
  {
    "text": "1.10 \"Calendar Year\"' shall mean each successive period of twelve (12) months commencing on January 1 and ending on.",
    "bbox": [
      179,
      343,
      1000,
      358
    ],
    "label": 5,
    "category": "Expiration Date"
  },
  {
    "text": "December 31, except that the first Calendar Year of the Term shall commence on the Effective Date and end on December 31 of",
    "bbox": [
      113,
      365,
      1000,
      377
    ],
    "label": 5,
    "category": "Expiration Date"
  },
  {
    "text": "the year in which the Effective Date occurs, and the last Calendar Year of the Term shall commence on January 1 of the year in",
    "bbox": [
      111,
      382,
      1000,
      397
    ],
    "label": 5,
    "category": "Expiration Date"
  },
  {
    "text": "which the Term ends and end on the last day of the Term.",
    "bbox": [
      113,
      402,
      595,
      415
    ],
    "label": 5,
    "category": "Expiration Date"
  },
  {
    "text": "1.11 \"Claims\"' shall mean all charges, complaints, actions, suits, proceedings, hearings, investigations, claims, demands,",
    "bbox": [
      179,
      436,
      1000,
      451
    ],
    "label": 5,
    "category": "Expiration Date"
  },
  {
    "text": "judgments, orders, decrees, stipulations or injunctions, in each case of a Third Party (including any Governmental Authority)",
    "bbox": [
      111,
      457,
      1000,
      471
    ],
    "label": 5,
    "category": "Expiration Date"
  },
  {
    "text": "1.12 \"Code\"' shall mean the Code on Interactions with Healthcare Professionals promulgated by the Pharmaceutical.",
    "bbox": [
      179,
      491,
      1000,
      506
    ],
    "label": 5,
    "category": "Expiration Date"
  },
  {
    "text": "Research and Manufacturers of America (PhRMA)/BIO, as it may be amended.",
    "bbox": [
      113,
      512,
      794,
      525
    ],
    "label": 5,
    "category": "Expiration Date"
  },
  {
    "text": "1.13 \"Compensation Report\"' shall have the meaning set forth in Section 4.2.2(b).",
    "bbox": [
      181,
      547,
      881,
      559
    ],
    "label": 5,
    "category": "Expiration Date"
  },
  {
    "text": "1.14 \"Compliance Manager\"' shall have the meaning set forth in Section 4.3.9.",
    "bbox": [
      179,
      581,
      857,
      597
    ],
    "label": 5,
    "category": "Expiration Date"
  },
  {
    "text": "1.15 \"Compliance Report' shall have the meaning set forth in Section 4.2.2(c).",
    "bbox": [
      181,
      619,
      859,
      633
    ],
    "label": 5,
    "category": "Expiration Date"
  },
  {
    "text": "1.16 \"Confidential Information'' shall mean all secret, confidential, non-public or proprietary Know-How, whether",
    "bbox": [
      180,
      654,
      1000,
      669
    ],
    "label": 5,
    "category": "Expiration Date"
  },
  {
    "text": "provided in written, oral, graphic, video, computer or other form, provided by or on behalf of one Party to the other Party",
    "bbox": [
      112,
      675,
      1000,
      689
    ],
    "label": 5,
    "category": "Expiration Date"
  },
  {
    "text": "pursuant to this Agreement, including information relating to the disclosing Party's existing or proposed research, development",
    "bbox": [
      112,
      694,
      1000,
      708
    ],
    "label": 5,
    "category": "Expiration Date"
  },
  {
    "text": "efforts, promotional efforts, regulatory matters, patent applications or business and any other materials that have not been made",
    "bbox": [
      111,
      713,
      1000,
      727
    ],
    "label": 5,
    "category": "Expiration Date"
  },
  {
    "text": "available by the disclosing Party to the general public. All such information related to this Agreement disclosed by or on behalf of a",
    "bbox": [
      111,
      731,
      1000,
      746
    ],
    "label": 5,
    "category": "Expiration Date"
  },
  {
    "text": "Party (or its Affiliate) to the other Party (or its Affiliate) pursuant to the Confidentiality Agreement shall be deemed to be such",
    "bbox": [
      112,
      751,
      1000,
      765
    ],
    "label": 5,
    "category": "Expiration Date"
  },
  {
    "text": "Party's Confidential Information disclosed hereunder. For purposes of clarity, (i) Dova's Confidential Information shall include all",
    "bbox": [
      111,
      769,
      1000,
      784
    ],
    "label": 5,
    "category": "Expiration Date"
  },
  {
    "text": "Product Materials unless and until made available by Dova to the general public (including through Valeant) and (ii) the terms of this",
    "bbox": [
      113,
      789,
      1000,
      802
    ],
    "label": 5,
    "category": "Expiration Date"
  },
  {
    "text": "Agreement shall be considered Confidential Information of both Parties.",
    "bbox": [
      114,
      808,
      719,
      821
    ],
    "label": 5,
    "category": "Expiration Date"
  },
  {
    "text": "1.17 \"Confidentiality Agreement' shall have the meaning set forth in Section 9.1.1.",
    "bbox": [
      180,
      842,
      903,
      857
    ],
    "label": 5,
    "category": "Expiration Date"
  },
  {
    "text": "3",
    "bbox": [
      660,
      895,
      672,
      906
    ],
    "label": 5,
    "category": "Expiration Date"
  },
  {
    "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
    "bbox": [
      415,
      983,
      918,
      992
    ],
    "label": 5,
    "category": "Expiration Date"
  },
  {
    "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
    "bbox": [
      133,
      1000,
      592,
      1000
    ],
    "label": 5,
    "category": "Expiration Date"
  },
  {
    "text": "protection and deceptive trade practices, including any state anti-kickback/fraud and abuse related laws, all as amended from time",
    "bbox": [
      111,
      141,
      1000,
      157
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "to time.",
    "bbox": [
      111,
      161,
      174,
      174
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "1.8 'Business Day' means each day of the week, excluding Saturday, Sunday or a day on which banking institutions in",
    "bbox": [
      180,
      195,
      1000,
      210
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "New York, New York. USA are closed..",
    "bbox": [
      111,
      216,
      455,
      229
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "1.9 \"Calendar Quarter\"' shall mean each successive period of three (3) calendar months commencing on January 1, April.",
    "bbox": [
      179,
      249,
      1000,
      266
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "1, July 1 and October 1, except that the first Calendar Quarter of the Term shall commence on the Effective Date and end on the",
    "bbox": [
      113,
      271,
      1000,
      284
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "day immediately prior to the first to occur of January 1, April 1, July 1 or October 1 after the Effective Date, and the last Calendar",
    "bbox": [
      112,
      290,
      1000,
      304
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "Quarter shall end on the last day of the Term..",
    "bbox": [
      114,
      310,
      493,
      322
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "1.10 \"Calendar Year\"' shall mean each successive period of twelve (12) months commencing on January 1 and ending on.",
    "bbox": [
      179,
      343,
      1000,
      358
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "December 31, except that the first Calendar Year of the Term shall commence on the Effective Date and end on December 31 of",
    "bbox": [
      113,
      365,
      1000,
      377
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "the year in which the Effective Date occurs, and the last Calendar Year of the Term shall commence on January 1 of the year in",
    "bbox": [
      111,
      382,
      1000,
      397
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "which the Term ends and end on the last day of the Term.",
    "bbox": [
      113,
      402,
      595,
      415
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "1.11 \"Claims\"' shall mean all charges, complaints, actions, suits, proceedings, hearings, investigations, claims, demands,",
    "bbox": [
      179,
      436,
      1000,
      451
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "judgments, orders, decrees, stipulations or injunctions, in each case of a Third Party (including any Governmental Authority)",
    "bbox": [
      111,
      457,
      1000,
      471
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "1.12 \"Code\"' shall mean the Code on Interactions with Healthcare Professionals promulgated by the Pharmaceutical.",
    "bbox": [
      179,
      491,
      1000,
      506
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "Research and Manufacturers of America (PhRMA)/BIO, as it may be amended.",
    "bbox": [
      113,
      512,
      794,
      525
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "1.13 \"Compensation Report\"' shall have the meaning set forth in Section 4.2.2(b).",
    "bbox": [
      181,
      547,
      881,
      559
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "1.14 \"Compliance Manager\"' shall have the meaning set forth in Section 4.3.9.",
    "bbox": [
      179,
      581,
      857,
      597
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "1.15 \"Compliance Report' shall have the meaning set forth in Section 4.2.2(c).",
    "bbox": [
      181,
      619,
      859,
      633
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "1.16 \"Confidential Information'' shall mean all secret, confidential, non-public or proprietary Know-How, whether",
    "bbox": [
      180,
      654,
      1000,
      669
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "provided in written, oral, graphic, video, computer or other form, provided by or on behalf of one Party to the other Party",
    "bbox": [
      112,
      675,
      1000,
      689
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "pursuant to this Agreement, including information relating to the disclosing Party's existing or proposed research, development",
    "bbox": [
      112,
      694,
      1000,
      708
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "efforts, promotional efforts, regulatory matters, patent applications or business and any other materials that have not been made",
    "bbox": [
      111,
      713,
      1000,
      727
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "available by the disclosing Party to the general public. All such information related to this Agreement disclosed by or on behalf of a",
    "bbox": [
      111,
      731,
      1000,
      746
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "Party (or its Affiliate) to the other Party (or its Affiliate) pursuant to the Confidentiality Agreement shall be deemed to be such",
    "bbox": [
      112,
      751,
      1000,
      765
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "Party's Confidential Information disclosed hereunder. For purposes of clarity, (i) Dova's Confidential Information shall include all",
    "bbox": [
      111,
      769,
      1000,
      784
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "Product Materials unless and until made available by Dova to the general public (including through Valeant) and (ii) the terms of this",
    "bbox": [
      113,
      789,
      1000,
      802
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "Agreement shall be considered Confidential Information of both Parties.",
    "bbox": [
      114,
      808,
      719,
      821
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "1.17 \"Confidentiality Agreement' shall have the meaning set forth in Section 9.1.1.",
    "bbox": [
      180,
      842,
      903,
      857
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "3",
    "bbox": [
      660,
      895,
      672,
      906
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
    "bbox": [
      415,
      983,
      918,
      992
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
    "bbox": [
      133,
      1000,
      592,
      1000
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "protection and deceptive trade practices, including any state anti-kickback/fraud and abuse related laws, all as amended from time",
    "bbox": [
      111,
      141,
      1000,
      157
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "to time.",
    "bbox": [
      111,
      161,
      174,
      174
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "1.8 'Business Day' means each day of the week, excluding Saturday, Sunday or a day on which banking institutions in",
    "bbox": [
      180,
      195,
      1000,
      210
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "New York, New York. USA are closed..",
    "bbox": [
      111,
      216,
      455,
      229
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "1.9 \"Calendar Quarter\"' shall mean each successive period of three (3) calendar months commencing on January 1, April.",
    "bbox": [
      179,
      249,
      1000,
      266
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "1, July 1 and October 1, except that the first Calendar Quarter of the Term shall commence on the Effective Date and end on the",
    "bbox": [
      113,
      271,
      1000,
      284
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "day immediately prior to the first to occur of January 1, April 1, July 1 or October 1 after the Effective Date, and the last Calendar",
    "bbox": [
      112,
      290,
      1000,
      304
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "Quarter shall end on the last day of the Term..",
    "bbox": [
      114,
      310,
      493,
      322
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "1.10 \"Calendar Year\"' shall mean each successive period of twelve (12) months commencing on January 1 and ending on.",
    "bbox": [
      179,
      343,
      1000,
      358
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "December 31, except that the first Calendar Year of the Term shall commence on the Effective Date and end on December 31 of",
    "bbox": [
      113,
      365,
      1000,
      377
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "the year in which the Effective Date occurs, and the last Calendar Year of the Term shall commence on January 1 of the year in",
    "bbox": [
      111,
      382,
      1000,
      397
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "which the Term ends and end on the last day of the Term.",
    "bbox": [
      113,
      402,
      595,
      415
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "1.11 \"Claims\"' shall mean all charges, complaints, actions, suits, proceedings, hearings, investigations, claims, demands,",
    "bbox": [
      179,
      436,
      1000,
      451
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "judgments, orders, decrees, stipulations or injunctions, in each case of a Third Party (including any Governmental Authority)",
    "bbox": [
      111,
      457,
      1000,
      471
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "1.12 \"Code\"' shall mean the Code on Interactions with Healthcare Professionals promulgated by the Pharmaceutical.",
    "bbox": [
      179,
      491,
      1000,
      506
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "Research and Manufacturers of America (PhRMA)/BIO, as it may be amended.",
    "bbox": [
      113,
      512,
      794,
      525
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "1.13 \"Compensation Report\"' shall have the meaning set forth in Section 4.2.2(b).",
    "bbox": [
      181,
      547,
      881,
      559
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "1.14 \"Compliance Manager\"' shall have the meaning set forth in Section 4.3.9.",
    "bbox": [
      179,
      581,
      857,
      597
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "1.15 \"Compliance Report' shall have the meaning set forth in Section 4.2.2(c).",
    "bbox": [
      181,
      619,
      859,
      633
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "1.16 \"Confidential Information'' shall mean all secret, confidential, non-public or proprietary Know-How, whether",
    "bbox": [
      180,
      654,
      1000,
      669
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "provided in written, oral, graphic, video, computer or other form, provided by or on behalf of one Party to the other Party",
    "bbox": [
      112,
      675,
      1000,
      689
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "pursuant to this Agreement, including information relating to the disclosing Party's existing or proposed research, development",
    "bbox": [
      112,
      694,
      1000,
      708
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "efforts, promotional efforts, regulatory matters, patent applications or business and any other materials that have not been made",
    "bbox": [
      111,
      713,
      1000,
      727
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "available by the disclosing Party to the general public. All such information related to this Agreement disclosed by or on behalf of a",
    "bbox": [
      111,
      731,
      1000,
      746
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "Party (or its Affiliate) to the other Party (or its Affiliate) pursuant to the Confidentiality Agreement shall be deemed to be such",
    "bbox": [
      112,
      751,
      1000,
      765
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "Party's Confidential Information disclosed hereunder. For purposes of clarity, (i) Dova's Confidential Information shall include all",
    "bbox": [
      111,
      769,
      1000,
      784
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "Product Materials unless and until made available by Dova to the general public (including through Valeant) and (ii) the terms of this",
    "bbox": [
      113,
      789,
      1000,
      802
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "Agreement shall be considered Confidential Information of both Parties.",
    "bbox": [
      114,
      808,
      719,
      821
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "1.17 \"Confidentiality Agreement' shall have the meaning set forth in Section 9.1.1.",
    "bbox": [
      180,
      842,
      903,
      857
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "3",
    "bbox": [
      660,
      895,
      672,
      906
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
    "bbox": [
      415,
      983,
      918,
      992
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
    "bbox": [
      133,
      1000,
      592,
      1000
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "protection and deceptive trade practices, including any state anti-kickback/fraud and abuse related laws, all as amended from time",
    "bbox": [
      111,
      141,
      1000,
      157
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "to time.",
    "bbox": [
      111,
      161,
      174,
      174
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "1.8 'Business Day' means each day of the week, excluding Saturday, Sunday or a day on which banking institutions in",
    "bbox": [
      180,
      195,
      1000,
      210
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "New York, New York. USA are closed..",
    "bbox": [
      111,
      216,
      455,
      229
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "1.9 \"Calendar Quarter\"' shall mean each successive period of three (3) calendar months commencing on January 1, April.",
    "bbox": [
      179,
      249,
      1000,
      266
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "1, July 1 and October 1, except that the first Calendar Quarter of the Term shall commence on the Effective Date and end on the",
    "bbox": [
      113,
      271,
      1000,
      284
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "day immediately prior to the first to occur of January 1, April 1, July 1 or October 1 after the Effective Date, and the last Calendar",
    "bbox": [
      112,
      290,
      1000,
      304
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "Quarter shall end on the last day of the Term..",
    "bbox": [
      114,
      310,
      493,
      322
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "1.10 \"Calendar Year\"' shall mean each successive period of twelve (12) months commencing on January 1 and ending on.",
    "bbox": [
      179,
      343,
      1000,
      358
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "December 31, except that the first Calendar Year of the Term shall commence on the Effective Date and end on December 31 of",
    "bbox": [
      113,
      365,
      1000,
      377
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "the year in which the Effective Date occurs, and the last Calendar Year of the Term shall commence on January 1 of the year in",
    "bbox": [
      111,
      382,
      1000,
      397
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "which the Term ends and end on the last day of the Term.",
    "bbox": [
      113,
      402,
      595,
      415
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "1.11 \"Claims\"' shall mean all charges, complaints, actions, suits, proceedings, hearings, investigations, claims, demands,",
    "bbox": [
      179,
      436,
      1000,
      451
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "judgments, orders, decrees, stipulations or injunctions, in each case of a Third Party (including any Governmental Authority)",
    "bbox": [
      111,
      457,
      1000,
      471
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "1.12 \"Code\"' shall mean the Code on Interactions with Healthcare Professionals promulgated by the Pharmaceutical.",
    "bbox": [
      179,
      491,
      1000,
      506
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "Research and Manufacturers of America (PhRMA)/BIO, as it may be amended.",
    "bbox": [
      113,
      512,
      794,
      525
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "1.13 \"Compensation Report\"' shall have the meaning set forth in Section 4.2.2(b).",
    "bbox": [
      181,
      547,
      881,
      559
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "1.14 \"Compliance Manager\"' shall have the meaning set forth in Section 4.3.9.",
    "bbox": [
      179,
      581,
      857,
      597
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "1.15 \"Compliance Report' shall have the meaning set forth in Section 4.2.2(c).",
    "bbox": [
      181,
      619,
      859,
      633
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "1.16 \"Confidential Information'' shall mean all secret, confidential, non-public or proprietary Know-How, whether",
    "bbox": [
      180,
      654,
      1000,
      669
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "provided in written, oral, graphic, video, computer or other form, provided by or on behalf of one Party to the other Party",
    "bbox": [
      112,
      675,
      1000,
      689
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "pursuant to this Agreement, including information relating to the disclosing Party's existing or proposed research, development",
    "bbox": [
      112,
      694,
      1000,
      708
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "efforts, promotional efforts, regulatory matters, patent applications or business and any other materials that have not been made",
    "bbox": [
      111,
      713,
      1000,
      727
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "available by the disclosing Party to the general public. All such information related to this Agreement disclosed by or on behalf of a",
    "bbox": [
      111,
      731,
      1000,
      746
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "Party (or its Affiliate) to the other Party (or its Affiliate) pursuant to the Confidentiality Agreement shall be deemed to be such",
    "bbox": [
      112,
      751,
      1000,
      765
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "Party's Confidential Information disclosed hereunder. For purposes of clarity, (i) Dova's Confidential Information shall include all",
    "bbox": [
      111,
      769,
      1000,
      784
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "Product Materials unless and until made available by Dova to the general public (including through Valeant) and (ii) the terms of this",
    "bbox": [
      113,
      789,
      1000,
      802
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "Agreement shall be considered Confidential Information of both Parties.",
    "bbox": [
      114,
      808,
      719,
      821
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "1.17 \"Confidentiality Agreement' shall have the meaning set forth in Section 9.1.1.",
    "bbox": [
      180,
      842,
      903,
      857
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "3",
    "bbox": [
      660,
      895,
      672,
      906
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
    "bbox": [
      415,
      983,
      918,
      992
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
    "bbox": [
      133,
      1000,
      592,
      1000
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "protection and deceptive trade practices, including any state anti-kickback/fraud and abuse related laws, all as amended from time",
    "bbox": [
      111,
      141,
      1000,
      157
    ],
    "label": 21,
    "category": "Minimum Commitment"
  },
  {
    "text": "to time.",
    "bbox": [
      111,
      161,
      174,
      174
    ],
    "label": 21,
    "category": "Minimum Commitment"
  },
  {
    "text": "1.8 'Business Day' means each day of the week, excluding Saturday, Sunday or a day on which banking institutions in",
    "bbox": [
      180,
      195,
      1000,
      210
    ],
    "label": 21,
    "category": "Minimum Commitment"
  },
  {
    "text": "New York, New York. USA are closed..",
    "bbox": [
      111,
      216,
      455,
      229
    ],
    "label": 21,
    "category": "Minimum Commitment"
  },
  {
    "text": "1.9 \"Calendar Quarter\"' shall mean each successive period of three (3) calendar months commencing on January 1, April.",
    "bbox": [
      179,
      249,
      1000,
      266
    ],
    "label": 21,
    "category": "Minimum Commitment"
  },
  {
    "text": "1, July 1 and October 1, except that the first Calendar Quarter of the Term shall commence on the Effective Date and end on the",
    "bbox": [
      113,
      271,
      1000,
      284
    ],
    "label": 21,
    "category": "Minimum Commitment"
  },
  {
    "text": "day immediately prior to the first to occur of January 1, April 1, July 1 or October 1 after the Effective Date, and the last Calendar",
    "bbox": [
      112,
      290,
      1000,
      304
    ],
    "label": 21,
    "category": "Minimum Commitment"
  },
  {
    "text": "Quarter shall end on the last day of the Term..",
    "bbox": [
      114,
      310,
      493,
      322
    ],
    "label": 21,
    "category": "Minimum Commitment"
  },
  {
    "text": "1.10 \"Calendar Year\"' shall mean each successive period of twelve (12) months commencing on January 1 and ending on.",
    "bbox": [
      179,
      343,
      1000,
      358
    ],
    "label": 21,
    "category": "Minimum Commitment"
  },
  {
    "text": "December 31, except that the first Calendar Year of the Term shall commence on the Effective Date and end on December 31 of",
    "bbox": [
      113,
      365,
      1000,
      377
    ],
    "label": 21,
    "category": "Minimum Commitment"
  },
  {
    "text": "the year in which the Effective Date occurs, and the last Calendar Year of the Term shall commence on January 1 of the year in",
    "bbox": [
      111,
      382,
      1000,
      397
    ],
    "label": 21,
    "category": "Minimum Commitment"
  },
  {
    "text": "which the Term ends and end on the last day of the Term.",
    "bbox": [
      113,
      402,
      595,
      415
    ],
    "label": 21,
    "category": "Minimum Commitment"
  },
  {
    "text": "1.11 \"Claims\"' shall mean all charges, complaints, actions, suits, proceedings, hearings, investigations, claims, demands,",
    "bbox": [
      179,
      436,
      1000,
      451
    ],
    "label": 21,
    "category": "Minimum Commitment"
  },
  {
    "text": "judgments, orders, decrees, stipulations or injunctions, in each case of a Third Party (including any Governmental Authority)",
    "bbox": [
      111,
      457,
      1000,
      471
    ],
    "label": 21,
    "category": "Minimum Commitment"
  },
  {
    "text": "1.12 \"Code\"' shall mean the Code on Interactions with Healthcare Professionals promulgated by the Pharmaceutical.",
    "bbox": [
      179,
      491,
      1000,
      506
    ],
    "label": 21,
    "category": "Minimum Commitment"
  },
  {
    "text": "Research and Manufacturers of America (PhRMA)/BIO, as it may be amended.",
    "bbox": [
      113,
      512,
      794,
      525
    ],
    "label": 21,
    "category": "Minimum Commitment"
  },
  {
    "text": "1.13 \"Compensation Report\"' shall have the meaning set forth in Section 4.2.2(b).",
    "bbox": [
      181,
      547,
      881,
      559
    ],
    "label": 21,
    "category": "Minimum Commitment"
  },
  {
    "text": "1.14 \"Compliance Manager\"' shall have the meaning set forth in Section 4.3.9.",
    "bbox": [
      179,
      581,
      857,
      597
    ],
    "label": 21,
    "category": "Minimum Commitment"
  },
  {
    "text": "1.15 \"Compliance Report' shall have the meaning set forth in Section 4.2.2(c).",
    "bbox": [
      181,
      619,
      859,
      633
    ],
    "label": 21,
    "category": "Minimum Commitment"
  },
  {
    "text": "1.16 \"Confidential Information'' shall mean all secret, confidential, non-public or proprietary Know-How, whether",
    "bbox": [
      180,
      654,
      1000,
      669
    ],
    "label": 21,
    "category": "Minimum Commitment"
  },
  {
    "text": "provided in written, oral, graphic, video, computer or other form, provided by or on behalf of one Party to the other Party",
    "bbox": [
      112,
      675,
      1000,
      689
    ],
    "label": 21,
    "category": "Minimum Commitment"
  },
  {
    "text": "pursuant to this Agreement, including information relating to the disclosing Party's existing or proposed research, development",
    "bbox": [
      112,
      694,
      1000,
      708
    ],
    "label": 21,
    "category": "Minimum Commitment"
  },
  {
    "text": "efforts, promotional efforts, regulatory matters, patent applications or business and any other materials that have not been made",
    "bbox": [
      111,
      713,
      1000,
      727
    ],
    "label": 21,
    "category": "Minimum Commitment"
  },
  {
    "text": "available by the disclosing Party to the general public. All such information related to this Agreement disclosed by or on behalf of a",
    "bbox": [
      111,
      731,
      1000,
      746
    ],
    "label": 21,
    "category": "Minimum Commitment"
  },
  {
    "text": "Party (or its Affiliate) to the other Party (or its Affiliate) pursuant to the Confidentiality Agreement shall be deemed to be such",
    "bbox": [
      112,
      751,
      1000,
      765
    ],
    "label": 21,
    "category": "Minimum Commitment"
  },
  {
    "text": "Party's Confidential Information disclosed hereunder. For purposes of clarity, (i) Dova's Confidential Information shall include all",
    "bbox": [
      111,
      769,
      1000,
      784
    ],
    "label": 21,
    "category": "Minimum Commitment"
  },
  {
    "text": "Product Materials unless and until made available by Dova to the general public (including through Valeant) and (ii) the terms of this",
    "bbox": [
      113,
      789,
      1000,
      802
    ],
    "label": 21,
    "category": "Minimum Commitment"
  },
  {
    "text": "Agreement shall be considered Confidential Information of both Parties.",
    "bbox": [
      114,
      808,
      719,
      821
    ],
    "label": 21,
    "category": "Minimum Commitment"
  },
  {
    "text": "1.17 \"Confidentiality Agreement' shall have the meaning set forth in Section 9.1.1.",
    "bbox": [
      180,
      842,
      903,
      857
    ],
    "label": 21,
    "category": "Minimum Commitment"
  },
  {
    "text": "3",
    "bbox": [
      660,
      895,
      672,
      906
    ],
    "label": 21,
    "category": "Minimum Commitment"
  },
  {
    "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
    "bbox": [
      415,
      983,
      918,
      992
    ],
    "label": 21,
    "category": "Minimum Commitment"
  },
  {
    "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
    "bbox": [
      133,
      1000,
      592,
      1000
    ],
    "label": 21,
    "category": "Minimum Commitment"
  },
  {
    "text": "protection and deceptive trade practices, including any state anti-kickback/fraud and abuse related laws, all as amended from time",
    "bbox": [
      111,
      141,
      1000,
      157
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "to time.",
    "bbox": [
      111,
      161,
      174,
      174
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "1.8 'Business Day' means each day of the week, excluding Saturday, Sunday or a day on which banking institutions in",
    "bbox": [
      180,
      195,
      1000,
      210
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "New York, New York. USA are closed..",
    "bbox": [
      111,
      216,
      455,
      229
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "1.9 \"Calendar Quarter\"' shall mean each successive period of three (3) calendar months commencing on January 1, April.",
    "bbox": [
      179,
      249,
      1000,
      266
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "1, July 1 and October 1, except that the first Calendar Quarter of the Term shall commence on the Effective Date and end on the",
    "bbox": [
      113,
      271,
      1000,
      284
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "day immediately prior to the first to occur of January 1, April 1, July 1 or October 1 after the Effective Date, and the last Calendar",
    "bbox": [
      112,
      290,
      1000,
      304
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "Quarter shall end on the last day of the Term..",
    "bbox": [
      114,
      310,
      493,
      322
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "1.10 \"Calendar Year\"' shall mean each successive period of twelve (12) months commencing on January 1 and ending on.",
    "bbox": [
      179,
      343,
      1000,
      358
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "December 31, except that the first Calendar Year of the Term shall commence on the Effective Date and end on December 31 of",
    "bbox": [
      113,
      365,
      1000,
      377
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "the year in which the Effective Date occurs, and the last Calendar Year of the Term shall commence on January 1 of the year in",
    "bbox": [
      111,
      382,
      1000,
      397
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "which the Term ends and end on the last day of the Term.",
    "bbox": [
      113,
      402,
      595,
      415
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "1.11 \"Claims\"' shall mean all charges, complaints, actions, suits, proceedings, hearings, investigations, claims, demands,",
    "bbox": [
      179,
      436,
      1000,
      451
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "judgments, orders, decrees, stipulations or injunctions, in each case of a Third Party (including any Governmental Authority)",
    "bbox": [
      111,
      457,
      1000,
      471
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "1.12 \"Code\"' shall mean the Code on Interactions with Healthcare Professionals promulgated by the Pharmaceutical.",
    "bbox": [
      179,
      491,
      1000,
      506
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "Research and Manufacturers of America (PhRMA)/BIO, as it may be amended.",
    "bbox": [
      113,
      512,
      794,
      525
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "1.13 \"Compensation Report\"' shall have the meaning set forth in Section 4.2.2(b).",
    "bbox": [
      181,
      547,
      881,
      559
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "1.14 \"Compliance Manager\"' shall have the meaning set forth in Section 4.3.9.",
    "bbox": [
      179,
      581,
      857,
      597
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "1.15 \"Compliance Report' shall have the meaning set forth in Section 4.2.2(c).",
    "bbox": [
      181,
      619,
      859,
      633
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "1.16 \"Confidential Information'' shall mean all secret, confidential, non-public or proprietary Know-How, whether",
    "bbox": [
      180,
      654,
      1000,
      669
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "provided in written, oral, graphic, video, computer or other form, provided by or on behalf of one Party to the other Party",
    "bbox": [
      112,
      675,
      1000,
      689
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "pursuant to this Agreement, including information relating to the disclosing Party's existing or proposed research, development",
    "bbox": [
      112,
      694,
      1000,
      708
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "efforts, promotional efforts, regulatory matters, patent applications or business and any other materials that have not been made",
    "bbox": [
      111,
      713,
      1000,
      727
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "available by the disclosing Party to the general public. All such information related to this Agreement disclosed by or on behalf of a",
    "bbox": [
      111,
      731,
      1000,
      746
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "Party (or its Affiliate) to the other Party (or its Affiliate) pursuant to the Confidentiality Agreement shall be deemed to be such",
    "bbox": [
      112,
      751,
      1000,
      765
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "Party's Confidential Information disclosed hereunder. For purposes of clarity, (i) Dova's Confidential Information shall include all",
    "bbox": [
      111,
      769,
      1000,
      784
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "Product Materials unless and until made available by Dova to the general public (including through Valeant) and (ii) the terms of this",
    "bbox": [
      113,
      789,
      1000,
      802
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "Agreement shall be considered Confidential Information of both Parties.",
    "bbox": [
      114,
      808,
      719,
      821
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "1.17 \"Confidentiality Agreement' shall have the meaning set forth in Section 9.1.1.",
    "bbox": [
      180,
      842,
      903,
      857
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "3",
    "bbox": [
      660,
      895,
      672,
      906
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
    "bbox": [
      415,
      983,
      918,
      992
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
    "bbox": [
      133,
      1000,
      592,
      1000
    ],
    "label": 33,
    "category": "Audit Rights"
  }
]